Kornimate/medical-research-clean huggingface dataset:
effect of auricular vagus nerve stimulation in women with migraine disease

Conditions: Chronic Migraine, Headache

Summary: the aim of the study was to investigate the effectiveness of non-invasive auricular vagus nerve stimulation on pain and pulse variability in women aged 18-55 years with migraine. it is also aimed to see the effects of vagus nerve stimulation from all directions by making pain, pulse, blood pressure and autonomic measurements.

migraine, a neurological disorder that causes severe disability, is characterized by recurrent moderate to severe attacks associated with vegetative symptoms. patients with frequent attacks may overuse drugs, which can lead to migraine chronization and headache. in the last decade, neuromodulatory approaches have been developed for the treatment of headaches that do not respond adequately to treatment. non-invasive neuromodulation techniques are an evolving field in migraine research and treatment. non-invasive vagus nerve stimulation is one of the non-invasive neuromodulation techniques. promising findings on vagus nerve stimulation in people with chronic pain, including migraine and cluster headaches, are slowly being recognized. stimulation of the vagus nerve provides a way of regulating autonomic tone. auricular vagus nerve stimulation regulates abnormal sympatho-vagal balance while activating the parasympathetic system, including anti-inflammatory pathways (cholinergic anti-inflammatory pathway and hypothalamic-pituitary adrenal axis). it is aimed to evaluate the effect on pain and pulse variability after vagus nerve stimulation in women with migraine disease and to learn how the vagus nerve crosses according to the pulse measurements taken from the right and left index fingers.

Eligibility criteria:
inclusion criteria: * people between the ages of 18-55 with migraine disease * having a definite diagnosis of migraine by a neurologist * absence of any orthopedic, neurological, etc. diseases that will prevent physical activity * not using drugs continuously except for migraine attacks * willingness to participate in the study * having signed the informed consent form exclusion criteria: * cases do not want to continue the study. * not signing the informed consent form * being on medication for migraine prophylaxis * having a communication problem that does not allow evaluation * having a history of additional chronic disease that interferes with physical activity, * pregnancy

Keywords: pulse rate variability pain
the antipyretic efficacy of oral and intravenous paracetamol and intramuscular diclofenac in patients presenting with fever.

Conditions: Fever; Reduction in Temperature

Summary: a randomized clinical trial to check the antipyretic efficacy of oral and intravenous paracetamol and intramuscular diclofenac sodium in patients presenting with fever to emergency department.


Eligibility criteria:
inclusion criteria: * adults between the age of 14-75 years with an oral temperature of more than 38.5 c exclusion criteria: * history of allergy to any of the drugs in the study * had taken antipyretics within 8 hours * renal, hepatic or haematological disorders * bronchial asthma, peptic ulcer disease, vomiting * pregnant or lactating women

Keywords: antipyretics oral paracetamol intravenous paracetamol intramuscular diclofenac emergency department
hypofractionated radiotherapy for recurrent dipg

Conditions: Recurrent Diffuse Intrinsic Pontine Glioma

Summary: this study evaluates the feasibility of hypofractionated radiotherapy (rt) in the palliative treatment of recurrent diffuse intrinsic pontine glioma (dipg). participants will receive 15 gy in 3 fractions as opposed to the standard 20 gy in 10 fractions.


Eligibility criteria:
inclusion criteria: 1. patients must be ≤30 years of age 2. patients must have a diagnosis of progressive dipg. 3. received prior imrt based definitive radiotherapy to a dose of ≥54 gy. 4. the patient and or parent/legal guardian must be physically and mentally capable of signing the consent form of their own volition. 5. steroids dosage must be unchanged for 5 days. 6. no bevacizumab within 21 days (half-life 11 days \~) exclusion criteria: 1. patients with incomplete medical records 2. patients with prior history of reirradiation for dipg 3. life expectancy \< or equal to 1 month 4. pregnant women 5. age \>30 6. prisoners 7. concurrent systemic therapy at the time of reirradiation 8. physically or mentally incapable of signing the consent form of their own volition 9. \< 6 mos time interval between completion of initial rt to start of rert.
a effectiveness trial of early hemodynamic support in patients demonstrating a low systolic blood pressure

Conditions: Intraoperative Low Blood Pressure

Summary: the investigators thus propose to use an innovative randomized effectiveness trial design to test the theory that early automatic identification of a ¡ low systolic blood pressure¡± clinical condition and decision-support alerts will prompt earlier hemodynamic support and a consequently reduce the duration of such conditions. specifically, the investigators will test the hypothesis that providing dss alerts in regards to hypotension reduces the duration of hypotensive episodes. the core of the investigators study will be an existing electronic anesthesia record and smart-alarm decision-support system. all patients undergoing surgery at hillcrest will be randomly assigned to routine care or to dss support. in patients assigned to dss support, a systolic blood pressure less than 80 mmhg will generate a warning within three minutes after detection. clinicians will be free to act on the alert, ignore the alert, or to consider the provided information without acting on it. the randomization, complete anesthesia record, detailed record of hypotensive events, alerts provided, clinician responses, and sap response, will be captured by the investigators electronic record-keeping system. the investigators primary outcome will be the duration of time the patient has a systolic blood pressure less than 80 mmhg. secondary outcome will be duration of hospitalization. the investigators will assess the effect of the alert on the primary outcome of time to sbp returning to above 80 mmhg using survival analysis, with time to event censored (and considered a non-event) at either the end of surgery or end of monitoring if patient did not return to above 80 mmhg.


Eligibility criteria:
inclusion criteria: * patients will be enrolled in the study if systolic blood pressure (sbp) is measured to be below 80 mmhg for at least 3 minutes, either with the arterial line or cuff (non-invasive blood pressure, nibp).
combining active living programme (alp) with home-use wearable technical aids (wta)

Conditions: Stroke; Foot Drop (Acquired)

Summary: the objective of this study is to evaluate the effectiveness of adopting a home-use wearable technical aids (wta) with the structured active living program (alp) to promote community participation in young stroke patients.

two groups of patients would receive wearable technical aids training or wearable technical aids training and structured active living program (alp) for 8 sessions.

Eligibility criteria:
inclusion criteria: -diagnosed with foot drop with tibialis anterior muscle strength between 1 to 3- out of 5 in manual muscle testing for more than six months due to cerebrovascular accident (cva) exclusion criteria: * pre-existing orthopedic conditions affecting ambulation * subjects who are incompetent in giving written consent

Keywords: wearable
a randomized, controlled phase iii trial of sorafenib with or without ctace in patients with advanced hcc

Conditions: Advanced Adult Hepatocellular Carcinoma

Summary: this is a randomized, multi-center, open-labeled, phase iii study in patients with advanced hcc. a total of 338 patients will be randomized (1:1) into one of the two treatment arms, to receive sorafenib with (arm combination-treatment; arm c) or without (arm sorafenib alone treatment; arm s) ctace. all the patients will be initially given sorafenib within 72 hours after the randomization. treatment should continue until the criteria for treatment discontinuation are met. after the treatment period, patients will undergo follow up for survival every 12 weeks (±7 days) from the last dose, and the survival follow up will be performed for at least 1.5 years after the last patient's last treatment.

the superiority of the arm c (ctace+sorafenib) over the arm s (sorafenib) in the os period will be verified in the itt set and fas using a stratified log-rank test. stratification factors consist of muicc stage (iii vs. iv), vascular invasion (none and vp1-2 vs. vp3-4 and any other presence), child-pugh score (5 vs. 6-7), serum afp level (≥200 ng/ml vs. \<200 ng/ml). the significance level is 5% (one-sided).

Eligibility criteria:
inclusion criteria: to be eligible to participate in the study, patients must meet the following criteria: 1. signed written informed consent 2. clinical or histological diagnosis of hcc based on the guidelines of the korean liver cancer study group and the national cancer center korea 3. at least one typical enhanced index lesion in the liver that is bi-dimensionally measurable by multiphasic spiral ct scan or dynamic contrast-enhanced mri, and size of largest tumor is 15 cm or less at enrollment. 4. tumor conditions confirmed by abdominal imaging (contrast enhanced ct ± mri) and chest imaging (ct) performed within 4 weeks prior to the treatment initiation: 5. age of at least 20 years. 6. ecog performance status of 0, 1 or 2. 7. child-pugh class a or b (child-pugh score ≤ 7). 8. life expectancy of at least 16 weeks. 9. adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements (no transfusion, no restoration), conducted within 14 days prior to screening: 10. female patients at least 1 year postmenopausal, surgically sterile or those of childbearing potential must have a negative urine pregnancy test within 14 days prior to the first treatment, and have to use at least one medically acceptable and effective contraceptive method for the last 2 months prior to screening visit: methods of effective contraception result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as a barrier method (implant, injectable contraceptives, oral contraceptives, intrauterine contraceptive device), hormonal iud, sexual abstinence or vasectomized partner. exclusion criteria:

Keywords: tace sorafenib
the prime study: a randomized, controlled, prospective study

Conditions: Patient Preference; Patient Outcomes; Post-Operative Inflammation; Grade of Post-Operative Cystoid Macular Edema; Rate of Post-Operative Cystoid Macular Edema

Summary: to investigate the outcomes of patients undergoing bilateral rle surgery with treatment of dexamethasone intracanilicular insert compared to topical standard care steroid. desiged to look at patient preference comparing the insert to drops and will also look at patient outcomes including inflammatin and risk of cystoid macular edema post-operatively.

a randomized, controlled, prospective study design in which one eye (group a) receives dextenza and the second eye (group b) receives prednisolone acetate 1% qid 1 week, tid 1 week, bid 1 week, and qd 1week, following bilateral rle surgery. all eyes will receive topical moxifloxacin qid for one week and topical ilevro qd for 4 weeks. moxifloxacin and ilevero are used in post-op regardless of the research. post-operative evaluations to be performed on day 1, day 7, and 1 month.

Eligibility criteria:
inclusion criteria: * any adult patient who is planned to undergo bilateral rle surgery with bcva 20/30 or better * willing and able to comply with clinic visits and study related procedures * willing and able to sign the informed consent form exclusion criteria: * patients under the age of 22 or above the age of 75 * patients who are pregnant (must be ruled out in a women of child-bearing age with pregnancy test). * patients with active infectious ocular or extraocular disease. * patients actively treated with local or systemic immunosuppression including systemic corticosteriods * paitents with know hypersensitivity to dexamethasone * patients with severe disease that warrants critical attentino, deemed unsafe for the study by the investigator * patients with a history of ocular inflammation or macular edema * patients with allergy or inability to receive intracameral antibiotic * patients on systemic non-steroidal anti-inflammatory drugs (nsaid) grater than 1,200 mg/day * patient with a corticosteriod implant (i.e. ozurdex). * patient with corneal pathology which pre-disposes them to unsatisfactory outcomes
study on post-acute covid-19 syndrome in improvement of covid-19 rehabilitated patients by respiratory training

Conditions: COVID-19; Post-Acute COVID-19 Syndrome; Dyspnea; Incentive Spirometer

Summary: since the emergence of corona virus disease 2019(covid-19), it has spread rapidly around the world, and it has had a profound impact on the lives and health of people around the world, most of the covid-19 positive patients are 3-4 weeks after the onset of infection patients can turn negative and recover, however, increasing observational data suggest that these patients long-term or recurring symptoms such as: fatigue, palpitations, cognitive impairment, dyspnea, anxiety, chest tightness and pain, etc., symptoms may last at least two months or even longer (for example, up to 12 months), the patient's quality of life and the ability to work and social activities also decline accordingly. therefore, in addition to the acute symptoms after infection, patients also face the same. the challenge of long-term health sequelae associated with covid-19.

relevant studies have shown that breathing training can improve the exercise capacity, lung function, and respiratory rate of patients who have recovered from covid-19. difficult and other aspects are safe and effective. however, because covid-19 is an emerging disease, the clinical research literature so far has limited clinical data are still insufficient, and the effect of respiratory training on the breathing and physical function of covid-19 patients has not been determined, and most of the patients are not living in the hospital. how to carry out simple and effective breathing training to reduce the long-term impact of covid-19 on patients is worthy of continuous discussion. this study will assist covid-19 patients to perform respiratory training with incentive spirometer intervention, and collect patients before and after the intervention oxygen requirements, blood draw values and post-covid-19 functional status scale(pcfs scale) and other data to explore and evaluate the effect of interventional breathing training on the improvement of symptoms of new coronary pneumonia, as a reference for future clinical treatment and improvement of symptoms of covid-19.

Eligibility criteria:
inclusion criteria: 1. patients who have recovered from covid-19 exclusion criteria: 1. have suffered from within one year. those who have recovered from covid-19 must present proof of diagnosis, such as a medical certificate or screening results, etc., and icd10 when seeking medical treatment the diagnostic codes are: u07.1 confirmed covid-19 virus infection, u09.0 severe specific infectious pneumonia (covid-19), unspecified. 2. adult, aged 20-90 3. conscious mind and behavior normal mental state examination (mini-mental state examination, mmse) score \> 21 points. 4. those who can communicate in verbal or non-verbal ways and understand chinese and taiwanese. 5. are willing to participate in the research and agree to accept random machine dispatcher
comparison of concentric or eccentric virtual reality training program in subacute-stroke patients with hemispatial neglect

Conditions: Stroke; Neglect

Summary: the purpose of this study is to compare and analyze how the visual gaze training in the afferent direction and the visual gaze training in the efferent direction using virtual reality affects the improvement of the neglect phenomenon in patients with subacute stroke with unilateral neglect. based on the behavioral intention test (bit) test and the mini-mental screening examination test (mmse) test for the group of unilateral neglected patients with stroke findings among all eligible patients for this experiment. appropriate subjects are selected and randomly divided into two groups. one group uses an afferent virtual reality program, and the other uses an efferent virtual reality program to train five times a week for a total of 4 weeks. before training, a computer experience scale 21 was additionally performed, and to find out the degree of unilateral negligence, evaluation was performed using the behavioral inattention test (bit) and catherine bergego scale (cbs)22, and the angle of deflection (deviation angle), out-of-focus time, gaze time, failure rate, and head rotation trajectory were evaluated. in addition, reaction time, failure rate, and head rotation trajectory were evaluated using a virtual reality program (assessment program-v2) to evaluate the degree of unilateral negligence. after that, bit, cbs, and assessment program-v2 tests are performed to determine the degree of improvement in visual ignorance due to each program.


Eligibility criteria:
inclusion criteria: 1. a person with left hemiplegia who was found to have a stroke by mri or ct. 2. a person who has been confirmed to have unilateral neglect (bit 196 or less, or each subtest cut off or less) 3. a person who has enough cognitive ability to receive virtual reality training. (in case of more than 20 points in mmse) 4. those within 3 months of onset. exclusion criteria: 1. those with a history of recurring brain damage 2. hemianopsia 3. when there is a disorder in the movement of the neck due to orthopedic problems 4. someone has vision and hearing problems during evaluation and treatment 5. difficult to maintain a sitting position in a chair with back and armrests 6. other diseases that may affect your general cognitive decline 7. who disagree with this study
effectiveness of sitagliptin in glycemic control in real world

Conditions: Type 2 Diabetes Mellitus

Summary: this study will evaluate whether the addition of sitagliptin treatment provides additional decrease in hba1c levels and increase in goal attainment in patients with inadequate glycemic control on their current oral anti-glycemic therapy in real world practice.

to explore the change of glycemic control (hba1c or fpg) before and after 24 weeks of sitagliptin treatment in type 2 diabetic patients who have started sitagliptin as add on therapy during the index period and received sitagliptin continuously\* for at least 24 weeks.

Eligibility criteria:
inclusion criteria: 1. all subjects diagnosed of type 2 diabetes (icd-9 code= 250.0; 250.1; 250.2; 250.3; 250.4; 250.5; 250.6) and have been followed up regularly in the study center who have started to receive sitagliptin as an add-on treatment to their prior regimen during the index period 2. subjects must be on a stable dose of all antidiabetic regimens, with stable dose defined as "at least 3 months with no therapy/dose change" prior to adding sitagliptin 3. subjects in whose medical records a minimum core data set can be found. 4. outpatient exclusion criteria: 1. subjects with type 1 dm 2. subjects have been treated with insulin regularly 3. subject with dm which results from other general diseases, e.g. surgery, pharmaceutical products, malnutrition, infections and other conditions 4. subjects who participated in a clinical trial or other clinical study during the index period

Keywords: retrospective,sitagliptin, glycemia control,real world
sodium bicarbonate to prevent acute kidney injury in children undergoing cardiac surgery

Conditions: Acute Kidney Injury; Congenital Heart Disease

Summary: the proposed study will investigate the effect of sodium bicarbonate on the prevention of acute kidney injury in children undergoing cardiac surgery with cardio-pulmonary bypass. the investigators hypothesize that the occurrence of acute kidney injury will be less in children treated with sodium bicarbonate in the perioperative period when compared to placebo. the specific aims of this proposal are as follows: 1. to institute a prospective, randomized, double-blinded, placebo-controlled trial in pediatric subjects undergoing cardiac surgery to determine the efficacy of sodium bicarbonate on prevention of acute kidney injury as measured by prifle criteria. 2. to examine whether treatment with sodium bicarbonate modifies the duration of acute kidney injury, fluid balance, hospital length of stay, need for dialysis, and progression to kidney failure. 3. to determine the relevance of ngal as a biomarker to predict development of acute kidney injury.


Eligibility criteria:
inclusion criteria: 1. subjects age ≤18 years 2. subjects scheduled for cardiac surgery with cardiopulmonary bypass exclusion criteria: 1. subjects with abnormal creatinine clearance (\<90 ml/min/1.7m2) as measured by the schwartz formula 2. subjects with known cystic kidney disease or posterior ureteral valves (subjects with solitary kidney, single multicystic/dysplastic kidney, hydronephrosis will not be excluded if renal function is preserved) 3. subjects with known metabolic disorder 4. premature infants born \<30 weeks gestation and \<30 days old due to risk of intraventricular hemorrhage subjects in severe cardiogenic shock post-operative requiring extra-corporeal membrane oxygenation (ecmo) or left ventricular assist device (lvad) will be withdrawn from the study.

Keywords: pediatric sodium bicarbonate acute kidney injury cardiac surgery
entities and variables related to catch-up growth

Conditions: Celiac Disease in Children

Summary: a retrospective monocentric observational no-profit study with the aim of evaluating the entity and potential variables influencing the catch-up growth of childhood gluten-free diet patients with celiac disease during a 10-year follow-up. the only extrapolation of the data collected in anonymized form from the medical records of patients who match the necessary study criteria will be planned in order to achieve this aim. a 900-patient sample size will be planned.


Eligibility criteria:
inclusion criteria: * celiac disease diagnosis established at the v. buzzi children\&#39;s hospital in milan between january 2010 and december 2020, excluding the extremes, in accordance with the espghan 2012 or 2020 recommendations. exclusion criteria: * patients with unclear or non-specific duodenal histological alterations (e.g., atrophy with unavailable or negative specific antibodies for celiac disease); * patients with additional chronic illnesses; * absence of the data required for the study; * patients with iga deficiency, defined as iga \&lt;20 mg/dl in children \&lt;3 years old or with levels that are below normal for their age.
the impact of resistance exercise training on metabolic dysregulation in obese children.

Conditions: Childhood Obesity; Body Composition; Resistance Training; Insulin Resistance

Summary: impact of resistance training in prepubertal children with obesity focusing mostly in changes in body composition and markers of insulin resistance. hypothesis is that this will show positive changes in this randomized controlled trial.

24 obese prepubertal obese children randomized to either resistance training program or usual care for 12 weeks. baseline blood profiles and dexa scans done before and after 12 weeks of training with the help of kinesiology graduates from concordia university kinesiology department.

Eligibility criteria:
inclusion criteria: * between 8-12y * prepubertal * not on medications with known impact on weight loss exclusion criteria: * pubertal * uncontrolled thyroid condition * type 2 diabetes

Keywords: resistance training obesity children